Actualités et Activités de BlueRock Therapeutics
Présence
Siège : Canada
Bayer fait partie des...
- Dax 40;
- Forbes Global 2000 (#618);
- Fortune 500 Europe (#69);
- Global Fortune 500 (#301);
- Stoxx 600;
- TOB Iconic 10,000.
Bayer est une société cotée sous le symbole boursier BAYN (DE).
Bayer a une présence directe dans 20 pays.Bayer a 39 filiales dont AskBio, Bayer ANZ et Bayer APAC.
Elles sont en:
- Pharmacie68%
- Biotechnologie15%
- Autre18%
Acquisition, funding and merger involving Bayer.
- Bayer has announced the acquisition of Perfuse Therapeutics (publié le 6 mai 2026).
Dirigeants
Voir l'organigramme avec ses 38 principaux dirigeants
Biographies les plus recherchées chez BlueRock Therapeutics
- Seth Ettenberg, Director, President and Chief Executive Officer
- Doug Kerr, Director
- Juergen Eckardt, Director
Changements de dirigeants chez BlueRock Therapeutics
- Stefan Irion, Chief Scientific Officer, a quitté l'entreprise (publié le 4 mai 2026).
Changements de dirigeants chez Bayer
- Judith Hartmann rejoindra l'entreprise comme Chief Financial Officer le 1 mai 2026 (publié le 8 novembre 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez BlueRock Therapeutics.
Biotechnologie
Bayer a 2 405 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et BioNTech (Allemagne).
Actualités en fusion/acquisition en Biotechnologie.
- IMU Biosciences vient d'annoncer une levée de fonds de 53 millions de dollars. (publié le 3 juin 2026).
- NewLimit vient d'annoncer une levée de fonds de 435 millions de dollars. (publié le 3 juin 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publié le 1 juin 2026)..
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par BlueRock Therapeutics
- News - BlueRock Therapeutics LP
- BlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell TherapyBlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell Therapy
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Diseas
- BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced
- Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine - Engineered Cell TherapySenti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Th
- BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases - Engineered Cell TherapyBlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis The
- BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell Therapy
- BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease - Engineered Cell Therapy
- BlueRock Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
- BlueRock Therapeutics President and CEO Emile Nuwaysir elected to serve as Vice Chairman of the Alliance for Regenerative Medicine
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de BlueRock Therapeutics
- BlueRock Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- BlueRock Therapeutics sur LinkedIn, X (Twitter) & YouTube en 1-click
